Insulin glulisine Pregnancy and Breastfeeding Warnings

Insulin glulisine is also known as: Apidra, Apidra Solostar

Insulin glulisine Pregnancy Warnings

Insulin glulisine given to animals throughout pregnancy at subcutaneous doses up to 10 units/kg once daily (an exposure 2 times the average human dose based on body surface area comparison) did not have any remarkable toxic effects on embryo-fetal development. Adverse effects on embryo-fetal development were only seen at maternal toxic dose levels inducing hypoglycemia. There are no controlled data in human pregnancy. Patients with diabetes or a history of gestational diabetes should maintain good metabolic control before conception and during pregnancy. Careful monitoring of glucose control is essential. FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

FDA pregnancy category: C Insulin glulisine should only be used if the benefit outweighs the risk to the developing fetus.

Insulin glulisine Breastfeeding Warnings

Caution is recommended Excreted into human milk: Unknown Excreted into animal milk: Data not available The effects in the nursing infant are unknown. The manufacturer states that the use of insulin glulisine is compatible with breastfeeding, but lactating diabetic women may require insulin dose adjustments.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.